Luybov V. Androsova

Luybov V. Androsova

Auto-generated profile, based on publicly available information

Luybov V. Androsova

FSBSI “Mental Health Research Centre

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
LAL. V. Androsova
L. V. Androsova
NMN. M. Mikhaĭlova
N. M. Mikhaĭlova
SZS. A. Zozulia
S. A. Zozulia
ADA. M. Dupin
A. M. Dupin
TKT. P. Kliushnik
T. P. Kliushnik
To identify inflammatory markers in schizophrenia in aged. The main group included 29 patients with schizophrenia, mean age 72.1 ± 6.9 years. A comparison group comprised 34 patients with Alzheimer's disease, mean age 73.4 ± 7.9 years. Seven plasma inflammatory indicators were determined. There was a significant increase in the activity/content of acute inflammation stage proteins: α1-proteinase inhibitor and C-reactive protein as well as anti-inflammatory interleukin-10 compared to the controls while the activity of other inflammatory molecules (leukocyte elastase, tumor necrosis factor alpha, interleukin-1 receptor antagonist) was not changed. No correlations between immunological parameters and clinical presentations were found. The results suggest that inflammation does not play a significant role in the remote stages of schizophrenia, in contrast to earlier stages of the disease, and the activity of the pathological process decreased in the late stages. These characteristics can reflect the body reactivity in elderly patients.

23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
EPE.V. Ponomareva
E.V. Ponomareva
LAL.V. Androsova
L.V. Androsova
SKS.A. Krinsky
S.A. Krinsky
SGSvetlana Gavrilova
Svetlana Gavrilova
OBJECTIVE To study the efficacy and safety of the use of annual course therapy of choline alfoscerate (CA) as a drug potentially capable of slowing or preventing the transition of amnesic type mild cognitive impairment (aMCI) into clinically pronounced dementia in a three-year open comparative study, as well as to explore the possibility of predicting the preventive effect of such therapy based on a number of clinical and biological parameters. MATERIAL AND METHODS The study included 100 patients with aMCI, randomly divided into 2 groups: the therapeutic group consisted of 50 patients who received CA course therapy once a year for 3 years (20 intravenous infusions of 1000 mg (4 ml) in 100 ml of saline solution for 4 weeks) and a comparison group of 50 patients who underwent an annual examination at the center and did not receive therapy. Clinical and psychopathological, psychometric, immunological, follow-up, and statistical methods were used. RESULTS A comparative three-year prospective study conducted in a group of aMCI patients treated with annual course therapy of CA for 3 years and aMCI patients who did not receive therapy with similar initial demographic, diagnostic, psychometric and immunological characteristics showed a lower progression of cognitive deficits (12.2% and 39.1%, respectively) and a lower conversion rate (8.2% and 26.1%, respectively) to dementia in the therapeutic group compared with the comparison group. The differences between the initial and final (after 1, 2 and 3 years of follow-up) cognitive functioning indicators in the therapeutic group and the comparison group were significant (p<0.05) on all scales and tests in favor of the therapeutic group throughout the entire follow-up period. CONCLUSION The results allow us to consider CA as a possible model of preventive dementia therapy aimed at preventing the progression of cognitive deficits and the development of dementia in people at high risk of developing AD — patients with aMCI.

1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
IKIgor Kolykhalov
Igor Kolykhalov
LAL.V. Androsova
L.V. Androsova
SGSvetlana Gavrilova
Svetlana Gavrilova
ЦЕЛЬ ИССЛЕДОВАНИЯ Определить динамику параметров клинико-иммунологической оценки состояния больных с синдромом мягкого когнитивного снижения амнестического типа (aMCI) в процессе проведения курсовой терапии холином альфосцератом (α-ГФХ) для разработки системы мониторинга и прогнозирования ее эффективности у лиц из группы риска развития болезни Альцгеймера (БА). МАТЕРИАЛ И МЕТОДЫ Тридцать пациентов в возрасте от 56 до 82 лет (средний возраст 68,8±9,4 года) с aMCI получали в течение 3 мес курсовую терапию α-ГФХ в капсулах по 400 мг 3 раза в день (1200 мг/сут). Оценка эффективности терапии по психометрическим тестам и шкалам проводилась трижды (0, 45 и 90-й дни терапии), дважды (0 и 90-й дни): оценивались иммунологические показатели — лейкоцитарная эластаза (ЛЭ) и α1-протеазный ингибитор (α1-ПИ). РЕЗУЛЬТАТЫ Было показано, что курсовое лечение α-ГФХ позволяет получить хороший терапевтический эффект в отношении как когнитивных функций, так и ряда иммунологических показателей у пациентов с aMCI. Выявленные значимые клинико-иммунологические корреляции между выраженностью улучшения когнитивных функций (по шкале MMSE и Бостонскому тесту называния 29 [28; 29] и 30 [29; 30] (p<0,05); 52 [51; 53] и 54 [52; 55] (p<0,05) на 45-й и 90-й дни терапии соответственно) и повышением уровня ЛЭ (229,0 [207,0; 246,2] нмоль/мин·мл, (p<0,05)) после завершения курсовой терапии α-ГФХ позволяют предположить, что связь между повышением активности ЛЭ может рассматриваться в качестве потенциального маркера позитивного терапевтического ответа на лечение α-ГФХ у пациентов с aMCI. ЗАКЛЮЧЕНИЕ Проведенное исследование показало возможность использования иммунологических показателей в качестве прогностических маркеров терапии и необходимость дальнейших исследований роли иммунных механизмов в терапевтическом эффекте α-ГФХ при aMCI.

1 January 2016 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
LAL. V. Androsova
L. V. Androsova
NSN. V. Simashkova
N. V. Simashkova
OSO. V. Shushpanova
O. V. Shushpanova
IOI. N. Otman
I. N. Otman
TKT. P. Kliushnik
T. P. Kliushnik
Издательство Медиа Сфера - 25 медицинских журналов общим тиражом около 500 000 экземпляров в год, представлены в международных базах данных Scopus, Medline, и Google Scolar, включены в перечень изданий ВАК, представлены в РИНЦ

25 November 2025 in Psychiatry (Moscow) (Psikhiatriya)
Verified
Journal Article
Open access
PDF file
EPE. V. Ponomareva
E. V. Ponomareva
SGSvetlana Gavrilova
Svetlana Gavrilova
LAL. V. Androsova
L. V. Androsova
SKS. A. Krinsky
S. A. Krinsky
ОСО. В. Сенько
О. В. Сенько
ЮЧЮ. А. Чайка
Ю. А. Чайка
Background: neuroinfiammation which occurs as a long-term latent activation of systemic infiammation in the central nervous system is currently considered as one of the main pathogenetic mechanisms of the neurodegeneration progression in the brain of patients with Alzheimer’s disease. The aim of study is to research the prognostic significance of clinical and immunological parameters determined in the blood serum of patients with amnestic Mild Cognitive Impairment (aMCI) and to form an immunological profile that determines the further dynamics of the syndrome. Patients and Methods : 261 outpatient with aMCI were followed up at the FSBSI “Mental Health Research Centre” in the period from 2014 to 2023. The study participants underwent a general clinical examination and assessment of cognitive functions using a battery of psychometric tests and scales (MMSE, MoCA, CDT, tests of 10 words and 5 geometric shapes memorization, the Hachinski ischemic scale). In addition, patients underwent an initial level of cytokines study (TNFa, IL-1, IL-1b, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10) in blood serum by enzyme immunoassay (ELISA); the levels of leukocyte elastase enzymatic activity (LE) and α1-proteinase inhibitor functional activity were determined in blood plazma by the spectrophotometric method. The protease inhibitory index was calculated. Conclusion: the cytokines set and immune response indicators have been identified. The distinguishing levels of TNFa, IL-6, IL-1b, LE predict various variants of three year course of aMCI including the conversion to dementia.

1 April 2020 in Neurochemical Journal
Verified
Journal Article
Closed access
PDF file
GBG. Sh. Burbaeva
G. Sh. Burbaeva
LAL. V. Androsova
L. V. Androsova
OSO. K. Savushkina
O. K. Savushkina
—One of the components of the cytoskeleton is microtubules (MT), a complex intracellular system, damage to which may cause disturbances that lead to the development of pathological processes in the cell. This gives rise to the study of tubulin, the main MT protein, in schizophrenia. To assess the relative amount of tubulin, its specific property to bind colchicine at an equimolar ratio was used. The aim of the study was to determine the level of colchicine binding (the colchicine-binding activity of tubulin) in various brain structures under normal conditions and in schizophrenia. The study was performed with samples of the structures of the postmortem brain of patients with schizophrenia (n = 7) and individuals in the control group (n = 15). The colchicine-binding activity of tubulin was determined using the Scherline method in tubulin-rich protein extracts (a single polymerization-depolymerization). In the prefrontal (area 10), limbic (area 23/24), and temporal (area 21) cerebral cortex of patients with schizophrenia, a significant decrease in the colchicine-binding activity of tubulin was observed in comparison with the control. In the thalamus, colchicine-binding activity in schizophrenia did not change relative to the control, but it was lower than in the areas of the cortex. In schizophrenia, we observed a decrease in the colchicine-binding activity of tubulin in the prefrontal (area 10), limbic (area 23/24), and temporal (area 21) cerebral cortex but not in the thalamus (subcortical structure of the brain).